Shots:

• The P-III MEASURE 1 and FUTURE 1 study involves assessing of Cosentyx (secukinumab) 75/ 150 mg vs PBO @16 wks. or 24 wks. in patients with PsA and AS respectively
• P-III MEASURE 1 (N=606) and FUTURE 1(N= 371) study results: improvement in ASAS 20 (74% @75mg- 82% @150mg)- improvement in signs and symptoms of PsA including enthesitis and dactylitis in 83% and 94% of patients respectively
• Cosentyx is a novel treatment that inhibits IL-17A- and is practiced >160-000 patients globally and is being tested in 100 studies

Ref: Novartis | Image: Financial Times